Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Increases in serum calcitonin, a tumor marker for medullary thyroid carcinoma (MTC), have been associated with glucagon-like peptide 1 receptor agonist use in some preclinical studies. We report calcitonin changes in exenatide-treated and placebo-administered participants and MTC incidence in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) and consider the impact of within-trial calcitonin monitoring. RESEARCH DESIGN AND METHODS: EXSCEL participants were randomized 1:1 to once-weekly exenatide 2 mg or placebo. Serum calcitonin was measured at baseline (with trial medication discontinued if >40 ng/L) and annually thereafter (with trial medication discontinued if ≥50 ng/L). Median calcitonin concentrations were calculated at each time point, and thyroid malignancies were collected prospectively. Data regarding follow-up after an elevated calcitonin were collected retrospectively. RESULTS: At baseline, 52 (30 exenatide and 22 placebo) participants had calcitonin >40 ng/L, and during follow-up an additional 23 participants (15 exenatide and 8 placebo) had calcitonin ≥50 ng/L in the intention-to-treat population. Median calcitonin concentrations were similar between treatment groups at baseline with no increase over time. Confirmed MTC occurred in three participants (2 exenatide and 1 placebo), all of whom had significantly elevated baseline calcitonin values (413, 422, and 655 ng/L). CONCLUSIONS: During a median 3.2 years’ follow-up, no change in serum calcitonin was seen with exenatide therapy. The three confirmed cases of MTC all occurred in participants with markedly elevated baseline calcitonin levels, measured prior to trial medication administration. Regular calcitonin monitoring identified no additional cases of MTC, suggesting no benefit of routine calcitonin monitoring during exenatide treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their analysis, three patients were diagnosed with MTC as they were found to have elevated calcitonin at baseline as part of study procedures. They identified 70 patients who had elevated calcitonin levels during the study, of which ∼53% underwent additional diagnostic testing without any additional thyroid cancer diagnoses.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RCT that evaluated the efficacy of GLP-1 RAs in individuals with diabetes or obesity have not shown a significantly increased risk of thyroid cancer.33,55,56”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Bethel et al. reported consistent findings of no increase in levels of calcitonin between patients in the placebo or exenatide arm of the EXSCEL trial.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“These findings highlight the potential burden of diagnostic cascades, in this case stemming from routine monitoring of calcitonin levels in patients on GLP-1 RA.55”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [55]
In the citing paper
“Calcitonin is a polypeptide secreted by thyroid C-cells that is involved with bone and calcium metabolism.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Neither liraglutide nor exenatide was associated with C-cell pathology in primates (3,6).”
BackgroundMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161 · cited 2×
“In contrast, preclinical studies with exenatide demonstrated increased incidence of C-cell adenomas (not carcinomas) in female rats at exposures 130 times the clinical dose and no C-cell pathology in mice (6).”
BackgroundResultThe Effects of Xenobiotics on the Structure and Function of Thyroid Follicular and C-Cells
Capen, C. C., & Martin, S. L. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700205 · Cited by 132
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 108
Self-citationDaniels, G. H. (2011) · Thyroid · doi:10.1089/thy.2010.0297 · Cited by 68
Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1956 · Cited by 67
Elisei, R., & Romei, C. (2013) · Thyroid Research · doi:10.1186/1756-6614-6-s1-s2 · Cited by 39
Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat
Martín‐Lacave, I., Bernabé, R., Sampedro, C., Conde, E., Fernández-Santos, J. M., Martín, M. V. S., Beato, A., & Galera-Davidson, H. (1999) · Cell and Tissue Research · doi:10.1007/s004410051371 · Cited by 19
Geller, G. S., Laskin, J. J., Cheung, W. Y., & Ho, C. (2017) · Thyroid Research · doi:10.1186/s13044-017-0041-6 · Cited by 17
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“25,26 Furthermore, a possible increase in overall thyroid cancer in GLP-1RA users has been reported in epidemiological studies 27,28 and clinical trials, 29 whereas other observational studies failed to detect either beneficial or detrimental effects of GLP-1RA on this endpoint.”
Metadata
- Authors
- Bethel, M. A., Patel, R. A., Thompson, V. P., Merrill, P., Reed, S. D., Li, Y., Ahmadi, S., Katona, B. G., Gustavson, S. M., Ohman, P., Iqbal, N., Gagel, R. F., Hernandez, A. F., Buse, J. B., & Holman, R. R.
- Affiliations
- University of Oxford (GB)
- Duke University (US)
- AstraZeneca (United States) (US)
- AstraZeneca Research and Development, Gaithersburg, MD
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Holman, Rury R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-04-22
- Volume
- 42
- Issue
- 6
- Pages
- 1075-1080
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973544
- OpenAlex
- W2936539025
- Semantic Scholar
- b2893dc37b0e0ef15fd57dcbb767b417415662aa
- Cited by
- 43
- References
- 14
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 3 · 2020: 4 · 2019: 2
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amylin Pharmaceuticals, Inc.
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- serum calcitonin, medullary thyroid carcinoma, exenatide, GLP-1 receptor agonists, EXSCEL trial, thyroid cancer incidence, type 2 diabetes, drug safety
- MeSH terms
- Exenatide, Adult, Aged, Calcitonin, Cardiovascular Diseases, Diagnostic Tests, Routine, Female, Follow-Up Studies, Humans, Male, Middle Aged, Monitoring, Physiologic, Retrospective Studies, Thyroid Hormones, Thyroid Neoplasms, Biomarkers, Tumor, Incidence, Carcinoma, Neuroendocrine, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.